PE20210043A1 - Dominio extracelular de subunidad alfa del receptor fc de ige, composicion farmaceutica que comprende el mismo y metodo para producir el mismo - Google Patents
Dominio extracelular de subunidad alfa del receptor fc de ige, composicion farmaceutica que comprende el mismo y metodo para producir el mismoInfo
- Publication number
- PE20210043A1 PE20210043A1 PE2020000919A PE2020000919A PE20210043A1 PE 20210043 A1 PE20210043 A1 PE 20210043A1 PE 2020000919 A PE2020000919 A PE 2020000919A PE 2020000919 A PE2020000919 A PE 2020000919A PE 20210043 A1 PE20210043 A1 PE 20210043A1
- Authority
- PE
- Peru
- Prior art keywords
- same
- ige
- extracellular domain
- alpha subunit
- pharmaceutical composition
- Prior art date
Links
- 102000009109 Fc receptors Human genes 0.000 title abstract 3
- 108010087819 Fc receptors Proteins 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000000539 dimer Substances 0.000 abstract 4
- 229920001184 polypeptide Polymers 0.000 abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 239000000178 monomer Substances 0.000 abstract 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- 108060003951 Immunoglobulin Proteins 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 235000018417 cysteine Nutrition 0.000 abstract 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 abstract 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 102000018358 immunoglobulin Human genes 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/304—Foods, ingredients or supplements having a functional effect on health having a modulation effect on allergy and risk of allergy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se refiere a un dimero de polipeptido, que comprende dos monomeros, cada uno de los cuales contiene un dominio extracelular (FcERIa-ECD) de una subunidad alfa de un receptor Fc de IgE, en donde el monomero contiene una region Fc modificada que esta unida mediante una bisagra al FcERIa-ECD. El dimero polipeptido, en donde el dominio extracelular de la subunidad alfa del receptor Fc de IgE es la secuencia de aminoacidos SEQ ID NO: 1 o un fragmento de la misma y la region Fc modificada es SEQ ID NO: 2. La bisagra es una region bisagra derivada de la inmunoglobulina IgD o una variante de la misma que contiene al menos una cisteina. Dicho dimero de polipeptido presenta una excelente capacidad de union a IgE, siendo util en el tratamiento o prevencion de una enfermedad alergica. Tambien se refiere a una composicion farmaceutica y un metodo para producir dicho dimero de polipeptido
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20180002248 | 2018-01-08 | ||
| PCT/KR2019/000274 WO2019135668A1 (ko) | 2018-01-08 | 2019-01-08 | Ige fc 수용체의 알파 서브유닛의 세포외 도메인, 이를 포함하는 약학적 조성물 및 이의 제조방법 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20210043A1 true PE20210043A1 (es) | 2021-01-08 |
Family
ID=67143676
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2020000919A PE20210043A1 (es) | 2018-01-08 | 2019-01-08 | Dominio extracelular de subunidad alfa del receptor fc de ige, composicion farmaceutica que comprende el mismo y metodo para producir el mismo |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20210070833A1 (es) |
| EP (1) | EP3738977A4 (es) |
| JP (2) | JP7128291B2 (es) |
| KR (1) | KR102038675B1 (es) |
| AU (1) | AU2019205743B2 (es) |
| BR (1) | BR112020013805A2 (es) |
| CA (1) | CA3086222A1 (es) |
| CL (1) | CL2020001798A1 (es) |
| IL (1) | IL275591B2 (es) |
| MX (1) | MX2020007030A (es) |
| PE (1) | PE20210043A1 (es) |
| PH (1) | PH12020551021A1 (es) |
| SG (1) | SG11202005858WA (es) |
| TW (1) | TWI713971B (es) |
| WO (1) | WO2019135668A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20210043A1 (es) | 2018-01-08 | 2021-01-08 | Gi Innovation Inc | Dominio extracelular de subunidad alfa del receptor fc de ige, composicion farmaceutica que comprende el mismo y metodo para producir el mismo |
| ES2969110T3 (es) * | 2018-01-12 | 2024-05-16 | Gi Innovation Inc | Composición que comprende probióticos y polipéptidos que tienen afinidad de unión por IgE y uso de la misma |
| BR112022000246A2 (pt) * | 2019-07-08 | 2022-02-22 | Gi Innovation Inc | Dímero polipeptídico com elevado teor de ácido siálico, compreendendo o domínio extracelular da subunidade alfa do receptor fc de ige e composição farmacêutica compreendendo o mesmo |
| US20230279124A1 (en) * | 2020-07-17 | 2023-09-07 | Gi Innovation, Inc. | Fusion protein comprising ige fc receptor alpha subunit extracellular domain and anti-il-4r antibody, and use thereof |
| KR20220011931A (ko) * | 2020-07-22 | 2022-02-03 | (주)지아이이노베이션 | IgE Fc 수용체를 포함하는 융합단백질 및 이를 포함하는 개 알레르기성 질환 치료 용도 |
| JP2024509937A (ja) | 2021-03-09 | 2024-03-05 | ジーアイ・イノベイション・インコーポレイテッド | Ｉｇｅ ｆｃ受容体のアルファサブユニットの細胞外ドメインを含む融合タンパク質の製剤 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3067334A (en) | 1959-03-13 | 1962-12-04 | Garrett Corp | Driving and control means for a plurality of alternators |
| DE60135158D1 (de) * | 2000-09-26 | 2008-09-11 | Genentech Inc | Antagonisten des ige-rezeptors |
| US7829084B2 (en) * | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
| DK1896071T3 (en) * | 2005-06-30 | 2015-05-26 | Janssen Biotech Inc | Methods and compositions with increased therapeutic activity |
| WO2008028068A2 (en) * | 2006-08-30 | 2008-03-06 | Genentech, Inc. | NON-HUMAN PRIMATE FCεR1α POLYPEPTIDES |
| US7867491B2 (en) * | 2007-05-30 | 2011-01-11 | Genexine Co., Ltd. | Immunoglobulin fusion proteins |
| DK2853545T3 (en) | 2008-09-17 | 2016-08-29 | Xencor Inc | Antibody specific for IgE |
| US20110256641A1 (en) * | 2010-04-19 | 2011-10-20 | Michael Ling | Methods and Systems for Detecting Free IgE |
| KR101825048B1 (ko) * | 2014-12-31 | 2018-02-05 | 주식회사 제넥신 | GLP 및 면역글로불린 하이브리드 Fc 융합 폴리펩타이드 및 이의 용도 |
| TWI691512B (zh) * | 2015-02-20 | 2020-04-21 | 日商橘生藥品工業股份有限公司 | Ｆｃ融合高親和性ＩｇＥ受體α鏈 |
| US10195272B2 (en) * | 2015-03-02 | 2019-02-05 | The Nemours Foundation | Adoptive t-cell therapy using FcεRI-based chimeric antigen receptors for treating IgE-mediated allergic diseases |
| KR101873201B1 (ko) * | 2015-06-11 | 2018-07-02 | 주식회사 제넥신 | 변형된 인터루킨-7 단백질 및 이의 용도 |
| KR102038672B1 (ko) * | 2018-01-08 | 2019-10-30 | (주)지아이이노베이션 | IgE Fc 수용체의 알파 서브유닛의 세포외 도메인을 포함하는 약학적 조성물 |
| PE20210043A1 (es) | 2018-01-08 | 2021-01-08 | Gi Innovation Inc | Dominio extracelular de subunidad alfa del receptor fc de ige, composicion farmaceutica que comprende el mismo y metodo para producir el mismo |
-
2019
- 2019-01-08 PE PE2020000919A patent/PE20210043A1/es unknown
- 2019-01-08 US US16/958,861 patent/US20210070833A1/en active Pending
- 2019-01-08 TW TW108100730A patent/TWI713971B/zh active
- 2019-01-08 JP JP2020557108A patent/JP7128291B2/ja active Active
- 2019-01-08 SG SG11202005858WA patent/SG11202005858WA/en unknown
- 2019-01-08 BR BR112020013805-3A patent/BR112020013805A2/pt unknown
- 2019-01-08 EP EP19735715.5A patent/EP3738977A4/en active Pending
- 2019-01-08 MX MX2020007030A patent/MX2020007030A/es unknown
- 2019-01-08 CA CA3086222A patent/CA3086222A1/en active Pending
- 2019-01-08 AU AU2019205743A patent/AU2019205743B2/en active Active
- 2019-01-08 KR KR1020190002029A patent/KR102038675B1/ko active IP Right Grant
- 2019-01-08 WO PCT/KR2019/000274 patent/WO2019135668A1/ko active Application Filing
-
2020
- 2020-06-22 IL IL275591A patent/IL275591B2/en unknown
- 2020-06-30 PH PH12020551021A patent/PH12020551021A1/en unknown
- 2020-07-03 CL CL2020001798A patent/CL2020001798A1/es unknown
-
2022
- 2022-08-18 JP JP2022130533A patent/JP7488303B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| BR112020013805A2 (pt) | 2020-12-01 |
| EP3738977A4 (en) | 2021-12-22 |
| SG11202005858WA (en) | 2020-07-29 |
| CN111587251A (zh) | 2020-08-25 |
| WO2019135668A1 (ko) | 2019-07-11 |
| RU2020122056A (ru) | 2022-02-10 |
| AU2019205743B2 (en) | 2023-11-16 |
| JP7488303B2 (ja) | 2024-05-21 |
| KR102038675B1 (ko) | 2019-10-30 |
| KR20190084885A (ko) | 2019-07-17 |
| JP2022176971A (ja) | 2022-11-30 |
| JP2021509590A (ja) | 2021-04-01 |
| JP7128291B2 (ja) | 2022-08-30 |
| IL275591B2 (en) | 2023-06-01 |
| EP3738977A1 (en) | 2020-11-18 |
| PH12020551021A1 (en) | 2021-05-31 |
| MX2020007030A (es) | 2020-12-03 |
| CL2020001798A1 (es) | 2020-11-13 |
| US20210070833A1 (en) | 2021-03-11 |
| TW201932488A (zh) | 2019-08-16 |
| AU2019205743A1 (en) | 2020-06-25 |
| TWI713971B (zh) | 2020-12-21 |
| IL275591A (en) | 2020-08-31 |
| CA3086222A1 (en) | 2019-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20210043A1 (es) | Dominio extracelular de subunidad alfa del receptor fc de ige, composicion farmaceutica que comprende el mismo y metodo para producir el mismo | |
| BR112022007627A2 (pt) | Compostos moduladores do glp-1r | |
| PE20211272A1 (es) | POLIPEPTIDOS DE IL-22 Y PROTEINAS DE FUSION DE IL-22 Fc Y METODOS DE USO | |
| HRP20211081T1 (hr) | Anti-pro/latentna miostatinska protutijela i njihove uporabe | |
| PE20191551A1 (es) | Polipeptidos de union al receptor de transferrina disenados | |
| BR112017001340A2 (pt) | vacinas antidengue e anticorpos | |
| AR085198A1 (es) | Composicion farmaceutica | |
| CO2019012998A2 (es) | Proteínas de unión a antígenos trem2 y usos de estas | |
| PE20190920A1 (es) | Anticuerpos modificados de union a fcrn humano y metodos de utilizacion | |
| CL2019003728A1 (es) | Moléculas de unión a antígeno que comprenden un trímero de ligando de la familia de tnf. (divisional solicitud 201701000) | |
| BR112018075396A2 (pt) | anticorpo neutralizante contra dengue para uso em um método de prevenção e/ou tratamento de infecção por zika | |
| EA202090641A1 (ru) | Мультиспецифическая антиген-связывающая молекула, обладающая замещающей функциональной активностью кофактора коагулирующего фактора крови viii, и фармацевтическая композиция, содержащая указанную молекулу в качестве активного ингредиента | |
| BR112016016411A2 (pt) | VARIANTES DE REGIÕES-"Fc" COM PROPRIEDADES DE LIGAÇÃO DE "FcRn" MODIFICADAS | |
| EA202092825A1 (ru) | Анти-sirpa антитела и способы их применения | |
| EA201792245A1 (ru) | Биоконъюгаты и их применения | |
| PE20190917A1 (es) | Compuestos del peptido tirosina ciclico con anticuerpo acoplado como moduladores de receptores de neuropeptido | |
| PE20120532A1 (es) | ANTICUERPOS ANTI-ActRIIB | |
| PE20190743A1 (es) | Metodos para el tratamiento de la atrofia muscular y enfermedad osea con el uso de proteinas trap hibridas novedosas del ligando actriib | |
| EA202091482A1 (ru) | Антитела | |
| EA201991511A1 (ru) | Кристаллическая структура гремлин-1 и ингибирующее антитело | |
| MD3497085T2 (ro) | Sulfonamide în calitate de agoniști ai GPR40- și GPR120- | |
| EA202092420A1 (ru) | Антитело против pd-l1 и его применение | |
| WO2016115511A3 (en) | Vegf variant polypeptide compositions | |
| EA202090649A1 (ru) | Агонисты рецептора глюкагоноподобного пептида 1 и их применения | |
| RU2017132689A (ru) | СЛИТАЯ С Fc α-ЦЕПЬ ВЫСОКОАФФИННОГО РЕЦЕПТОРА IgE |